Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.

doi:10.1158/1078-0432.CCR-23-0411

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2023

Das Anirban, Tabori Uri, Sambira Nahum Lauren C, Collins Natalie B, Deyell Rebecca, Dvir Rina, Faure-Conter Cecile, Hassall Timothy E, Minturn Jane E, Edwards Melissa, Brookes Elissa, Bianchi Vanessa, Levine Adrian, Stone Simone C, Sudhaman Sumedha, Sanchez Ramirez Santiago, Ercan Ayse B, Stengs Lucie, Chung Jill, Negm Logine, Getz Gad, Maruvka Yosef E, Ertl-Wagner Birgit, Ohashi Pamela S, Pugh Trevor, Hawkins Cynthia, Bouffet Eric, Morgenstern Daniel A

Abstract excerpt

PURPOSE: Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch repair deficiency (MMRD). PATIENTS AND METHODS: Twenty patients were screened, and 10 were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Colorectal Neoplasms

Share to DNA Mismatch Repair

Share to Glioma

Share to Neoplastic Syndromes, Hereditary

Share to Nivolumab

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37126021
DOI: 10.1158/1078-0432.CCR-23-0411
PMCID: PMC10690097

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.PMID 37126021Read ↗

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.Semantic proximity Read ↗

Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.Semantic proximity Read ↗

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiencySemantic proximity Read ↗

Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children with Germline DNA Replication Repair DeficiencySemantic proximity Read ↗

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.Semantic proximity Read ↗

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read ↗

The impact of molecularly matched treatment and tumor mutational burden on pediatric brain tumor patient outcomesSemantic proximity Read ↗

An update on central nervous system tumors in germline replication-repair deficiency syndromesSemantic proximity Read ↗

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.Semantic proximity Read ↗

Immuno-oncologic profiling of pediatric CNS tumors reveals major clinical significance of the tumor immune microenvironmentSemantic proximity Read ↗

Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.Semantic proximity Read ↗

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.